Paris

• A Long-term Study to Evaluate Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia Ended
  2023-508754-26-00 4 2017-02-10 Achondroplasia
• A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab ( … Ended
  2024-515000-39-00 9 2017-01-17 Recurrent glioblastoma.
• Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oe … Ended
  2024-515221-29-00 10 2016-12-19 Locally advanced or metastatic oesogastric adenocarcinoma
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha … Ended
  2024-511967-26-00 5 2016-11-21 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 5 2016-09-16 Metastatic renal cell carcinoma
• ROLLOVER STUDY FOR TAZEMETOSTAT Ended
  2023-510553-41-00 9 2016-08-29 Subjects will receive tazemetostat as dictated in their antecedent stu
• A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractor … Ended
  2022-500400-22-00 5 2016-06-23 Hodgkin lymphoma
• "A study to learn how well the drug larotrectinib works in adults with different solid cancers with a change in the genes called NTRK fusion … Ended
  2022-502667-38-00 4 2016-06-20 Solid tumors harboring NTRK fusion
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patient … Ended
  2024-512790-27-00 7 2016-04-19 Treatment of X-linked Chronic Granulomatous Disease
• Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG Ended
  2022-502526-41-00 4 2016-03-15 Non-Muscle Invasive Bladder Cancer (NMIBC)
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
• BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended
  2024-518931-12-00 4 2014-05-15 Neuroblastoma
• THIS IS A CLINICAL STUDY WHICH EVALUATES TREATMENT WITH CHLORAMBUCIL AND RITUXIMAB FOLLOWED BY RITUXIMAB GIVEN UNDER THE SKIN IN PATIENTS W … Ended
  2023-507291-52-00 4 2014-03-24 Extranodal Marginal Zone Lymphoma
• Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended
  2023-506419-16-00 5 2013-01-08 Advanced Classical Hodgkin Lymphoma
• Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple … Ended
  2022-500339-35-01 4 Multiple Myeloma
• Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended
  2022-502316-36-00 11 Symptomatic Obstructive Hypertrophic Cardiomyopathy
• C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended
  2022-502822-41-00 9 Relapsed/Refractory Diffuse Large B Cell Lymphoma
• A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended
  2022-503007-22-00 4 Non-small Cell Lung Cancer
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metast … Ended
  2022-503080-15-00 1 Cancer
• A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended
  2023-503348-15-00 7 Hodgkin lymphoma or non-Hodgkin lymphoma
• PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc … Ended
  2023-503807-27-00 4 Biliary tract carcinoma
• Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended
  2023-504963-17-00 9 Advanced ccRCC
• A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with … Ended
  2023-506240-16-00 9 Acute Myeloid Leukemia (AML)

Showing 2,233–2,256 of 2,286 trials